TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Patient portrayal. 
Individual results may vary.

TRINTELLIX relieved the overall symptoms of MDD1

Based on MADRS or HAM-D24 total scores, as shown in 6 short-term (6- to 8-week) MDD studies.

See Clinical Data

HAM-D24, Hamilton Depression 24-item Rating Scale;
MADRS, Montgomery-Åsberg Depression Rating Scale

Expert Insights

Hear directly from your peers as they spotlight MDD and how TRINTELLIX may help.

TRINTELLIX has been prescribed to over
2 million patients in the US.11

Quote: "My major depressive disorder is multiple symptoms that affect me in so many different ways. I wasn't sure what to do about it. Except to ask for help. So I told my doctor how I was struggling. Together, we agreed it was time for a change and came up with a treatment plan. I'm so grateful."

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.

Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

CONTINUE
CANCEL

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. Int J Neuropsychopharmacol. 2012;15(5):589‑600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. J Clin Psychiatry. 2012;73(7):953‑959.
  4. Boulenger J-P, Loft H, Olsen CK. Int Clin Psychopharmacol. 2014;29(3):138‑149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. Psychopharmacology (Berl). 2015;232(12):2061‑2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. J Clin Psychiatry. 2015;76(5):575‑582.
  7. Katona C, Hansen T, Olsen CK. Int Clin Psychopharmacol. 2012;27(4):215‑223.
  8. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Mult Scler. 2017;23(6):772‑789.
  9. McIntyre RS, Lophaven S, Olsen CK. Int J Neuropsychopharmacol. 2014;17(10):1557‑1567.
  10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. Neuropsychopharmacology. 2015;40(8):2025‑2037.
  11. Data on file. Takeda Pharmaceuticals.
  12. Data on file. Lundbeck.
  13. FDA updates Trintellix® (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute Major Depressive Disorder (MDD). News release. GlobeNewswire. May 2, 2018.
  14. Boulenger J-P, Loft H, Florea I. J Psychopharmacol. 2012;26(11):1408‑1416.
  15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. J Sex Med. 2015;12(10):2036‑2048.
  16. Kambeitz JP, Howes OD. J Affect Disord. 2015;186:358-366.
  17. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155‑188.